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CDK4/6 inhibitorThe cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway
controls cell cycle progression by regulating the G1-S checkpoint. Dysregulation of the cyclin
D-CDK4/6-INK4-Rb pathway results in increased proliferation, and is frequently observed in many types
of cancer. Pathway activation can occur through a variety of mechanisms, including gene amplification or
rearrangement, loss of negative regulators, epigenetic alterations, and point mutations in key pathway
components. Due to the importance of CDK4/6 activity in cancer cells, CDK4/6 inhibitors have emerged
as promising candidates for cancer treatment. Moreover, combination of a CDK4/6 inhibitor with other
targeted therapies may help overcome acquired or de novo treatment resistance. Ongoing studies include
combinations of CDK4/6 inhibitors with endocrine therapy and phosphatidylinositol 3-kinase (PI3K)
pathway inhibitors for hormone receptor-positive (HR+) breast cancers, and with selective RAF and
MEK inhibitors for tumors with alterations in the mitogen activated protein kinase (MAPK) pathway such
as melanoma. In particular, the combination of CDK4/6 inhibitors with endocrine therapy, such as palbo-
ciclib’s recent first-line approval in combination with letrozole, is expected to transform the treatment of
HR+ breast cancer. Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage
development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219). Here we
describe the current preclinical and clinical data for these novel agents and discuss combination
strategies with other agents for the treatment of cancer.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of
CDK4 (INK4)-retinoblastoma (Rb) pathway regulates cellular
proliferation by controlling the G1 (pre-DNA synthesis) to
S (DNA synthesis) cell cycle checkpoint. Dysregulation of the cyclin
D-CDK4/6-INK4-Rb pathway is frequently observed in cancer and
contributes to cell cycle progression and continued growth [1].
CDK4/6 mediates the transition from G1 to S phase by associating
with D-type cyclins and regulating the phosphorylation state of
Rb (Fig. 1A). Unphosphorylated Rb binds and represses the func-
tion of E2 family (E2F) transcription factors; upon phosphorylation,
Rb dissociates from E2F transcription factors, freeing them to be
able to participate in DNA replication and cell division. Increased
cyclin D-CDK4/6 activity, which promotes phosphorylation of Rb,
can occur through several mechanisms, including overexpression
of D-type cyclins, mutation or amplification of CDK4/6, or loss of
cyclin D-CDK4/6 negative regulators such as p16INK4A [1–3], and
ultimately leads to cancer cell growth. Thus, the development ofselective CDK4/6 inhibitors offers a novel therapeutic approach
for patients with advanced cancer.
This review will discuss how the cyclin D-CDK4/6-INK4-Rb
pathway becomes dysregulated, the resulting effects of pathway
activation, and the rationale for inhibiting CDK4/6 in cancer. It will
also provide an overview of the preclinical and clinical data for key
CDK4/6 inhibitors currently under investigation, and will examine
combination approaches that may be exploited in various
cancer types.Overview of the cyclin D-CDK4/6-INK4-Rb pathway in cancer
The cell cycle is broadly divided into four sequential phases:
G1 (pre-DNA synthesis), S (DNA synthesis), G2 (pre-division), and
M (cell division). The key regulator of the G1-S transition is the
cyclin D-CDK4/6-INK4-Rb pathway (Fig. 1A) [1]. CDK4 and CDK6
share 71% amino acid identity and have largely overlapping
functions [4]. Both kinases are expressed in most cell types—albeit
to different extents—and both can partner with all three D-type
cyclins (D1, D2, and D3) [4]. Upon activation by mitogenic signal-
ing pathways, D-type cyclins associate with CDK4 or CDK6. These
active cyclin D-CDK4/6 complexes phosphorylate Rb, and thereby
Fig. 1. (A) Overview of the cyclin D-CDK4/6-INK4-Rb pathway. (B) CDK4/6 inhibition results in decreased levels of phosphorylated Rb, promoting formation of
Rb-E2F complexes and preventing E2F transcription factor activity. Abbreviations: CDK, cyclin-dependent kinase; E2F, E2 transcription factor; Rb, retinoblastoma protein.
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complex. The released E2F transcription factors are then free to acti-
vate genes required for entry into S phase and DNA replication [1,5].
CDK4/6 activity is regulated by the INK4 family of proteins
(p16INK4A, p15INK4B, p18INK4C, and p19INK4D) and by the Cip and
Kip family (particularly p21CIP1 and p27KIP1) [5]. The INK4 proteins
inhibit cyclin D-CDK4/6 activity by directly binding to the CDK [5].
Of the four INK4 proteins, p16INK4A appears to be particularly
important for tumor suppression [1]. p21CIP1 and p27KIP1 have
context-dependent positive and negative effects on CDK4/6
activity; both can stabilize cyclin D-CDK4/6 complexes and bothpossess CDK4/6-inhibitory activity under certain conditions,
creating a complex system of regulation [6].
While loss of Rb is responsible for G1-S transition in some can-
cer types, the vast majority of cancers retain wild-type Rb [1].
These Rb-positive (Rb+) cancers can instead be driven by overex-
pression or activation of cyclin D-CDK4/6, loss of cyclin
D-CDK4/6 negative regulators, or by oncogenic signaling pathways
that promote cyclin D-CDK4/6 activity, and are likely to be depen-
dent on CDK4/6 activity for cell proliferation. Key oncogenic signal-
ing pathways that promote cyclin D-CDK4/6 activity include
phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of
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wnt/b-catenin, janus kinase (JAK)-signal transducer and activator
of transcription (STAT), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-jB), and steroid hormone signal-
ing pathways (e.g. estrogen, progesterone, and androgen) [7].
These pathways converge at the point of cyclin D-CDK4/6
signaling (Fig. 1A) [7].Mechanisms of cyclin D-CDK4/6-INK4-Rb pathway activation
Amplification of the genes encoding cyclin D1 (CCND1), CDK4,
or CDK6, or deletion of the locus encoding p16INK4A
(cyclin-dependent kinase inhibitor 2A [CDKN2A]) are major
mechanisms by which the cyclin D-CDK4/6-INK4-Rb pathway
can be activated. For example, the ProfiLER study (NCT01774409)
characterized genomic alterations in advanced cancers (N = 105;
breast, head and neck, and lung cancers accounted for >50% of
cases) and identified amplifications in CCND1 (17% of cases),
CDK4 (4%), and CDK6 (3%), as well as homozygous deletion of
CDKN2A (21%) [8]. Other studies in breast cancer have reported
CDK4 amplification in 16% of cases, CDK6 amplification in 17%,
and loss of p16INK4A in 49% [9,10]. CCND1 amplification is seen in
up to 35% of breast cancer cases, while the cyclin D protein is
overexpressed in over 50% [9,11]. Amplification of CCND1 is also
frequently observed in head and neck cancer (26–39% of cases),
non-small cell lung cancer (NSCLC; 5–30%), endometrial carcinoma
(26%), and pancreatic cancer (25%) [11]. Similarly, almost 50% of
prostate cancers overexpress CDK6 [12], and overexpression or
copy number variation of at least one cyclin D-CDK4/6-INK4-Rb
pathway component occurs in most cases of melanoma (approxi-
mately 75%) [13], head and neck squamous cell carcinoma (loss
of p16INK4A in approximately 80%) [14], and almost all cases of
liposarcoma and neuroblastoma [15–18].
Similarly, specific mutations or translocations in the genes
encoding cyclin D-CDK4/6-INK4-Rb pathway components can also
result in aberrant pathway activation. For example, mutation of
CDK4 at R24 prevents p16INK4A binding, resulting in enhanced
kinase activity [5]. CDK4 R24 mutations were first characterized
in familial melanoma [19], and were identified in 2.5% of mela-
noma cases in a whole-exome sequencing study [20]. This study
also identified mutations in the p16INK4A transcript (21% of
melanoma cases), CCND1 amplification (11%), and CDK4
amplification (3%) [20]. Mutation of the CDKN2A locus, encoding
p16INK4A, is also associated with melanoma; at least 20% of familial
melanoma cases are estimated to harbor mutations in this gene [21].
In a study of melanoma-prone families, the presence of a CDKN2A
mutation in the family increased the prevalence of other cancers
by 2–3-fold, including pancreatic, lung, and breast cancers [22].
Meanwhile, the hallmark of mantle cell lymphoma (MCL) is the
t(11;14) translocation, which juxtaposes the CCND1 coding region
to the IgH gene, resulting in constitutive overexpression of cyclin
D1 and cell cycle dysregulation in virtually all cases [5,23,24].
Dysregulation of the cell cycle machinery in MCL is also often asso-
ciated with CDK4 and CDK6 overexpression, or reduction in
p16INK4A expression through deletion or transcriptional
inhibition [24,25].
Multiple other mechanisms exist by which the
cyclin D-CDK4/6-INK4-Rb pathway can be activated. Epigenetic
alterations have been reported in ovarian cancer where repressive
promoter methylation at the CDKN2A gene was higher than in cor-
responding benign ovarian tissue biopsies [26]. Mutations in
upstream factors can also deregulate the cyclin D-CDK4/6-INK4-Rb
pathway, as is the case in malignant rhabdoid tumors (MRTs)
where the SMARCB1/INI1/SNF5 tumor suppressor gene is often
inactivated [27]. A critical function of SMARCB1 is to restrict activityof cyclin D-CDK4/6 through direct transcriptional repression of
CCND1 and increased expression of the negative regulators p21CIP1
and p16INK4A [28,29]. Downregulation of microRNAs (miRNAs) that
target CDK4/6 has also been associated with cancer. For example,
miRNAs that target CDK4 and CDK6 have been found to be downreg-
ulated in bladder cancer as compared with normal tissues [30,31].
Finally, dysregulation of upstream signaling pathways can also acti-
vate the cyclin D-CDK4/6-INK4-Rb pathway, as described earlier [7].Inhibiting CDK4/6 in cancer
Due to the importance of CDK4/6 activity in regulating cell pro-
liferation and the mechanisms by which this pathway is known to
be activated in cancer, selective inhibition of CDK4/6 inhibitors has
emerged as an attractive therapeutic strategy [32]. A major theo-
retical concern is that CDKs play a critical role in the proliferation
of normal cells as well as cancer cells, potentially creating a narrow
therapeutic windowwhere toxicity would limit the ability to attain
clinically effective exposure levels. To date, the most well-studied
pan-CDK inhibitor is flavopiridol, which showed limited clinical
benefit, partly due to its complex pharmacokinetics and high levels
of off-target side effects [1,33]. It is possible that cancers with
known aberrations in the cyclin D-CDK4/6-INK4-Rb pathway will
be more sensitive to CDK4/6 inhibition than normal cells [32].
Furthermore, selective inhibitors spare CDK2 activity which allows
normal cells to continue to function and proliferate. Highly selec-
tive CDK4/6 inhibitors may therefore have a wider therapeutic
window and fewer off-target toxicities than pan-CDK inhibitors.
Currently there are three CDK4/6 inhibitors that are either
approved or in late-stage development (Fig. 1B): palbociclib
(PD-0332991; Pfizer), ribociclib (LEE011; Novartis), and abemaciclib
(LY2835219; Lilly). All three compounds inhibit CDK4 and CDK6
with IC50 values <40 nM, although they exhibit varying IC50 values
against other CDKs (Table 1); such differences in selectivity may
influence their optimal dosing schedules and side effect profiles
(see below). All three compounds have also demonstrated preclin-
ical activity in a range of Rb+ tumor models (Table 1) [5,34–38].
Interestingly, cell lines with loss or mutation of CDKN2A, or loss
of p16INK4A protein expression, are particularly sensitive to palbo-
ciclib [13,39–41], although other preclinical models suggest that
CDK4/6 inhibition may still be an effective strategy in tumors
lacking these alterations [35,42].
Although CDK4/6 inhibition reduces proliferation and leads to
cell cycle arrest, cellular senescence or senescence-like activity
are likely to be important mechanisms associated with clinical
activity. Cellular senescence is the process by which a cell under-
goes permanent, irreversible growth arrest in response to cellular
stresses (e.g. unresolved DNA damage), rendering it resistant to
mitogenic stimulation and oncogenic challenge [43]. While a vari-
ety of biomarkers for cellular senescence exist, there is currently a
lack of consensus regarding the exact biomarkers or combination
of biomarkers to accurately measure senescence, which can
confound interpretation of data regarding cellular activity [43].
Nevertheless, palbociclib-induced, senescence-associated (SA)
b-galactosidase activity was markedly higher in melanoma cells
than in normal melanocytes, indicating that melanoma cells are
particularly reliant on CDK4/6-mediated suppression of senes-
cence or senescence-like activity [44]. One possible mechanism
of CDK4/6 inhibitor-induced senescence is through downregula-
tion of the forkhead box M1 (FOXM1) transcription factor [44].
Indeed, ribociclib-induced reduction in FOXM1 messenger RNA
(mRNA) and protein levels in ribociclib-sensitive neuroblastoma
cell lines was associated with induction of cellular senescence, as
measured using SA b-galactosidase activity [45]. In contrast,
ribociclib-resistant cell lines showed no reduction of FOXM1
Table 1
Characteristics of key CDK4/6 inhibitors in development.
Palbociclib (PD-0332991; Pfizer) Ribociclib (LEE011; Novartis) Abemaciclib
(LY2835219; Lilly)
IC50 (nM) [34,37,38]
CDK4-cyclin D1 11 10 2
CDK6-cyclin D1/2/3 15 39 10
CDK1-cyclin B >10,000 113,000 1627
CDK2-cyclin A/E >10,000 76,000 504
CDK9-cyclin T NR NR 57
Antitumor activity in xenograft
models [5,34–38,42,45,89]
MCL, myeloma, breast, lung, brain,
and colon cancer
Breast cancer, MCL, MRT, liposarcoma, melanoma, neuroblastoma AML, NSCLC,
glioblastoma,
colorectal, and lung
cancer
Predictors of resistance or
sensitivity [13,39–42,90]
Resistance: activation of the SHH
pathway in melanoma cell lines
Sensitivity: loss/mutation of CDKN2A
or loss of p16INK4A protein expression
in a range of cell lines
Sensitivity: KRAS
mutations in NSCLC
models
Half-life [91] 27 h NR NR
MTD/RP2D [47,52,54] 125/125 mg/day on a 21-of-28-day
schedule
900/600 mg/day on a 21-of-28-day schedule 200 mg twice daily
DLTs [47,52,54] Neutropenia (n = 5; 12%) Neutropenia (n = 3; 4%); asymptomatic thrombocytopenia (n = 2;
3%); mucositis, pulmonary embolism, hyponatremia, QTcF
prolongation (>500 ms), increased creatinine (n = 1; 1% each)
Fatigue (n = 3; 33%)
AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; CDKN2A, cyclin-dependent kinase inhibitor 2A; DLT, dose-limiting toxicity; IC50, half maximal inhibitory concentration;
KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MCL, mantle cell lymphoma; MRT, malignant rhabdoid tumor; MTD, maximum tolerated dose;
NR, not reported; NSCLC, non-small cell lung cancer; QTcF, QT corrected with Fridericia’s formula; RP2D, recommended phase II dose; SHH, sonic hedgehog.
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undergo senescence or senescence-like activity [45]. For
abemaciclib, a pharmacokinetic/pharmacodynamic model, using
topoisomerase IIa expression, phospho-histone H3 expression,
and Rb phosphorylation as markers of cell cycle progression,
demonstrated that chronic dosing to achieve a minimum
steady-state trough plasma concentration of 200 ng/mL is required
to maintain durable cell cycle arrest, and higher doses may be
needed to induce quiescence and cell death [46].Monotherapy approaches with CDK4/6 inhibitors
Palbociclib
The first-in-human phase I dose escalation study of palbociclib
was conducted in 41 patients with advanced solid tumors [47],
who were prescreened to confirm the presence of Rb expression
(Rb+). The maximum tolerated dose (MTD) and recommended
phase II dose (RP2D) of single-agent palbociclib were declared to
be 125 mg/day on a 21-of-28 day schedule (Table 1). Five patients
(12%) experienced dose-limiting toxicities (DLTs), all of which were
neutropenia. Beyond Cycle 1, the most common grade 3 adverse
events were neutropenia (n = 5; 12%) and anemia (n = 3; 7%;
Table 2). The most common all-grade non-hematologic adverse
events after Cycle 1 included fatigue (n = 10; 24%), diarrhea
(n = 6; 15%), nausea, dyspnea, and arthralgia (n = 5; 12% each).
Pharmacokinetic exposures to palbociclib following a single dose
were generally dose-proportional. At steady state (Day 21), palbo-
ciclib was absorbed with a median Tmax of approximately 5.5 h and
half-life of approximately 26 h. With repeated dosing, the median
accumulation ratio was 2.2. Pharmacodynamic decreases in neu-
trophil and platelet counts correlated with increasing palbociclib
exposure. During the 7-day rest period in Cycle 1, both cell types
recovered, with platelet levels exceeding baseline values; indicat-
ing this effect was fully reversible. Preliminary signs of clinical
activity were observed, with ten patients (27%) achieving stable
disease (SD) for at least 4 cycles and six patients (16%) having SD
for at least 10 cycles (of 37 evaluable patients) [47].Palbociclib monotherapy has since been studied in a variety of
tumor types. In a single-arm study, five of 17 patients with
relapsed MCL remained progression-free for more than 1 year on
palbociclib therapy, with one complete response (CR) and two par-
tial responses (PRs) [48]. In a phase II trial of palbociclib in 28
patients with metastatic Rb+ breast cancer, two patients achieved
PR [49]. In a separate phase II trial in 30 patients with Rb
+ advanced well-differentiated liposarcoma (WDLS) or dedifferen-
tiated liposarcoma (DDLS), palbociclib treatment resulted in a
12-week progression-free survival (PFS) rate of 66% [50]. Finally,
in a phase II trial of palbociclib in 19 patients with previously trea-
ted, advanced NSCLC exhibiting Rb expression and CDKN2A inacti-
vation (negative p16INK4A expression), the median PFS was
12.5 weeks, and five patients remained on study for at least
24 weeks [51].Ribociclib
The initial phase I dose escalation study of single-agent riboci-
clib enrolled 128 patients with Rb+ advanced solid tumors and
lymphomas (NCT01237236). The MTD and RP2D were declared
as 900 and 600 mg/day, respectively, on a 21-of-28-day schedule
(Table 1) [52]. DLTs included neutropenia (n = 3), thrombocytope-
nia (n = 2), mucositis, pulmonary embolism, hyponatremia,
increased creatinine, and asymptomatic QTC prolongation
(n = 1 each). The most common treatment-related adverse events
were neutropenia (45%), leukopenia (44%), nausea (43%), and
fatigue (42%) [52]. Grade 3/4 adverse events included neutropenia,
leukopenia, and lymphopenia (Table 2). Asymptomatic QT cor-
rected with Fridericia’s formula (QTcF) prolongation (>450 ms)
was seen at doses of greater than 600 mg/day (10% of patients at
600 mg/day and 27% of patients at higher doses) [52]. The
half-life was approximately 36 h, and paired skin biopsies from
40 patients showed reductions of at least 50% from baseline in
Ki67 and phosphorylated Rb, in 55% and 42% of the samples,
respectively. Among 110 evaluable patients, three had confirmed
PRs: one patient with head and neck acinar carcinoma and CDKN2A
loss, one patient with PIK3CA-mutant, CCND1-amplified,
estrogen receptor-positive (ER+) breast cancer, and one
Table 2
Single-agent clinical trials of CDK4/6 inhibitors.
Trial details Grade 3/4 adverse events overall
(P10% of patients)
Clinical activity
Palbociclib
NCT00141297 [47]: phase I dose escalation in patients with Rb+
advanced solid tumors (N = 41). MTD/RP2D: 125/125 mg/day on
a 21-of-28-day schedule
Neutropenia (20%), leukopenia (10%)
in Cycle 1
27% SD for P4 cycles; 16% SD for P10 cycles
(n = 37 evaluable)
NCT00420056 [48]: PK study of palbociclib (125 mg/day on a
21-of-28-day schedule) in patients with MCL (N = 17)
Neutropenia (36%), thrombocytopenia
(24%), hypophosphatemia (12%)
6% CR, 12% PR, 41% SD (n = 16 evaluable)
NCT01037790 [49]: phase II study of palbociclib (125 mg/day on a
21-of-28-day schedule) in patients with metastatic Rb + breast
cancer (N = 36)
Neutropenia (50%),
thrombocytopenia (21%)
7% PR; median PFS 4.1 months for ER+/HER2,
18.8 months for ER+/HER2+, 1.8 months for
ER/HER2 patients (n = 28 evaluable)
NCT01209598 [50]: phase II study of palbociclib (200 mg/day on a
14-of-21-day schedule) in patients with advanced
CDK4-amplified well-differentiated or dedifferentiated
liposarcoma (N = 30)
Neutropenia (50%), leukopenia (47%),
thrombocytopenia (30%),
lymphopenia (27%), anemia (17%)
3% PR, 12-week PFS 66%, median PFS 18 weeks
(n = 29 evaluable)
NCT01291017 [51]: phase II study of palbociclib (125 mg/day on a
21-of-28-day schedule) in patients with previously treated,
advanced, Rb+, CDKN2A-inactivated (p16INK4A expression
negative) NSCLC (N = 19)
Neutropenia (16%) 50% SD; median PFS 12.5 weeks
Ribociclib
NCT01237236 [52]: phase I dose escalation and expansion study in
patients with advanced solid tumors (N = 128). MTD/RP2D:
900/600 mg/day on a 21-of-28-day schedule
Neutropenia (26%), leukopenia (16%),
lymphopenia (16%)
3% PR, 37% SD (n = 110 evaluable)
NCT01747876 [53,92]: phase I dose escalation study in pediatric
patients with MRT, neuroblastoma, and cyclin D-CDK4/6-INK4-Rb
pathway-activated tumors (N = 31). MTD/RP2D:
470/350 mg/m2/day (adult equivalent dose 800/600 mg/day)
on a 21-of-28-day schedule
Neutropenia (61%), leukopenia (32%),
thrombocytopenia (29%),
lymphopenia (23%)
13% SD
Abemaciclib
NCT01394016 [54]: phase I study in patients with advanced cancer
(escalation phase n = 33; whole study N = 75). MTD: 200 mg
twice daily
– 2% PR, 2% CA-125 response (ovarian cancer, n = 1),
70% SD
NCT01394016 [55]: NSCLC expansion cohort (n = 57) dosed at MTD
or lower
Leukopenia (14%) 4% PR, 46% SD, 49% DCR (38% for KRAS wild-type
and 55% for KRAS mutant), median PFS 2.1 months
NCT01394016 [56]: metastatic breast cancer expansion cohort
(n = 47) dosed at MTD or lower
– 19% PR, DCR 70% (81% for HR+), median PFS
5.8 months (9.1 months for HR+)
CDK, cyclin-dependent kinase; CDKN2A, cyclin-dependent kinase inhibitor 2A; CR, complete response; DCR, disease control rate; ER, estrogen receptor; ER+, ER-positive;
ER, ER negative; HER2, human epidermal growth factor receptor 2; HER2+, HER2-positive; HER2, HER2 negative; HR+, hormone receptor-positive; INK4, inhibitor of CDK4;
KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MCL, mantle cell lymphoma; MRT, malignant rhabdoid tumor; MTD, maximum tolerated dose;
NSCLC, non-small cell lung cancer; PFS, progression-free survival; PK; pharmacokinetic; PR, partial response; Rb, retinoblastoma; Rb+, Rb-positive; RP2D, recommended phase II dose;
SD, stable disease.
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Prolonged SD for at least 4 and 6 cycles was seen in 24% and 15%
of patients, respectively [52].
A second study investigated ribociclib in pediatric patients
(aged 1–21 years) with MRTs, neuroblastoma, or other
cyclin D-CDK4/6-INK4-Rb pathway-activated tumors. In the dose
escalation portion of this phase I study, the MTD and
recommended dose for expansion (RDE) were declared to be
470 mg/m2/day (adult equivalent dose 800 mg/day) and
350 mg/m2/day (adult equivalent dose 600 mg/day), respectively,
on a 21-of-28-day schedule [53]. Ribociclib was well tolerated in
the pediatric population, with a similar safety profile to that seen
in adult patients [53].Abemaciclib
The first-in-human phase I trial of abemaciclib enrolled
75 patients with advanced solid tumors [54]. The dose escalation
phase explored once-daily and twice-daily (every 12 h) dosing on
a continuous schedule. Although the MTD for once-daily dosing
was not reached, the MTD for twice-daily dosing was declared
as 200 mg. The DLT was grade 3 fatigue in one of six patients at
200 mg and two of three patients at 275 mg. The most common
all-grade treatment-related adverse events included diarrhea
(52%), nausea (32%), fatigue, vomiting (21% each), and
neutropenia (19%). The most common grade 3 treatment-relatedadverse events were diarrhea, neutropenia (7% each), fatigue, and
nausea (5% each). At 200 mg, mean Cmax at steady state was
291 ng/mL and AUC0–24h was 5798 ngh/mL. Pharmacodynamic
evidence of targeted CDK4/6 inhibition was observed, as shown
by a decrease in Rb phosphorylation in the skin. One patient with
CDKN2A/, NRAS-mutant melanoma had a confirmed PR, and pro-
longed SD or minor radiographic decreases were seen in patients
with ovarian cancer, NSCLC, and breast cancer [54]. One of the
expansion cohorts from this study enrolled 57 patients with NSCLC
[55]. There were 2 PRs, and 12 patients (of which 8 had KRAS-
mutant disease) received treatment for P6 months. Another
expansion cohort enrolled 47 patients with metastatic breast can-
cer [56]. Nine PRs were observed, all in patients with HR+ breast
cancer (Table 2); the median PFS was 5.8 months, rising to
9.1 months for patients with HR+ breast cancer [56]. Based on
these results, in October 2015 the Food and Drug Administration
(FDA) granted abemaciclib a ‘Breakthrough Therapy’ designation
with ‘Fast Track’ status for the treatment of advanced breast
cancer [57].Combination approaches with CDK4/6 inhibitors
The greatest benefit of CDK4/6 inhibitors will likely lie in com-
bination with other therapies, and a range of phase III trials are
currently ongoing (Table 3).
Table 3
Phase III clinical trials of CDK4/6 inhibitors [64].
Agent Trial ID/name Patient population Combination agents Primary
endpoint
Breast cancer
Advanced, first line
Palbociclib NCT01740427/PALOMA-2 Postmenopausal women with ER+/HER2 ABC with no prior systemic
anticancer therapies for advanced/metastatic disease
Letrozole PFS
NCT02297438/PALOMA-4 Asian postmenopausal women with ER+/HER2 ABC with no prior systemic
anticancer therapies for advanced/metastatic disease
Letrozole PFS
Ribociclib NCT01958021/MONALEESA-2 Postmenopausal women with HR+/HER2 ABC Letrozole PFS
NCT02422615/MONALEESA-3 Postmenopausal women with HR+/HER2 ABC (first and second line) Fulvestrant PFS
NCT02278120/MONALEESA-7 Premenopausal women with HR+/HER2 ABC Tamoxifen or NSAI
plus goserelin
PFS
Abemaciclib NCT02246621/MONARCH 3 Postmenopausal women with HR+/HER2 locoregionally recurrent or
metastatic breast cancer
Anastrozole or
letrozole
PFS
NCT02107703/MONARCH 2 HR+/HER2 locally advanced or metastatic breast cancer Fulvestrant PFS
Advanced, second line
Palbociclib NCT02028507/PEARL Patients with HR+/HER2 metastatic breast cancer resistant to NSAI
treatment
Exemestane vs
chemotherapy
(capecitabine)
PFS
NCT01942135/PALOMA-3 Patients with HR+/HER2 metastatic breast cancer whose disease has
progressed after prior endocrine therapy; pre- and perimenopausal women
must be receiving goserelin
Fulvestrant PFS
Neoadjuvant
Palbociclib NCT01864746/PENELOPE-B HR+/HER2 breast cancer with residual disease after neoadjuvant
chemotherapy
Standard hormonal
therapy
Invasive
disease-free
survival
Lung cancer
Non-small cell
Abemaciclib NCT02152631/JUNIPER Stage IV NSCLC with a detectable KRAS mutation who have progressed after
platinum-based chemotherapy
– PFS, OS vs
erlotinib
Squamous cell
Palbociclib NCT02154490/Lung-MAP Recurrent stage IIIB-IV SCLC positive for CDK4/6, CCND1, CCND2, and CCND3
expression
– PFS, OS vs
docetaxel
Trial information obtained from ClinicalTrials.gov as of June 2015.
ABC, advanced breast cancer; CDK, cyclin-dependent kinase; ER+, estrogen receptor-positive; HER2, human epidermal growth factor receptor 2; HER2, HER2 negative;
HR+, hormone receptor-positive; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NSAI, non-steroidal aromatase inhibitor; NSCLC, non-small cell lung cancer;
OS, overall survival; PFS, progression-free survival; SCLC, small cell lung cancer.
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Hormonal therapy (or endocrine therapy) is the
standard-of-care treatment for HR+ breast cancer. HR+ breast can-
cers express either or both of the estrogen receptor (ER) or proges-
terone receptor (PgR), and account for up to 70% of all breast
cancers. Endocrine therapy blocks the hormone signaling that HR
+ breast cancer cells rely on to grow and divide; however, up to
50% of HR+ breast cancers become resistant to endocrine therapy
(acquired resistance) or demonstrate initial (de novo) resistance [7].
Endocrine therapy-resistant breast cancer cell lines and primary
luminal B breast cancers, which are known to respond poorly to
endocrine therapy, exhibit cyclin D-CDK4/6-INK4-Rb pathway acti-
vation and may be sensitive to CDK4/6 inhibition [58]. In addition,
CCND1 amplification has been identified in up to 35% of breast can-
cers, while overexpression of the cyclin D protein is even more
frequent [9,11,59,60]. Palbociclib has been shown to inhibit
proliferation of endocrine therapy-resistant breast cancer cells in
preclinical models [58]. Moreover, addition of ribociclib to
letrozole or fulvestrant enhanced inhibition of tumor growth in
ER+ xenograft models [61].
PALOMA-1/TRIO-18 was the first randomized, placebo-
controlled phase II trial to test the addition of a CDK4/6 inhibitor
(palbociclib) to an aromatase inhibitor (letrozole) as initial treat-
ment for postmenopausal women with ER+, human epidermal
growth factor receptor 2 (HER2)-negative advanced breast
cancer (N = 165). Combination of palbociclib with letrozole almost
doubled PFS from 10.2 months to 20.2 months compared with
letrozole alone (hazard ratio [HR] = 0.488, p = 0.0004) [62].No biomarker was identified that predicted response to palboci-
clib; increased PFS was observed regardless of CCND1 amplification
and loss of p16INK4A [62]. An interim overall survival (OS) analysis
suggested a trend in favor of the palbociclib plus letrozole combi-
nation (37.5 vs 33.3 months; HR = 0.813, p = 0.42) [62]. Based on
the results of PALOMA-1, the combination of palbociclib and letro-
zole was granted accelerated FDA approval in February 2015 for
the first-line treatment of HR+ metastatic breast cancer [63].
Continued approval is contingent on the results of a larger phase
III study (PALOMA-2; NCT01740427), identical in design to
PALOMA-1, which has completed accrual and is in the
follow-up phase [64].
Addition of palbociclib to endocrine therapy has also demon-
strated clinical efficacy in the second-line setting. In the phase III
PALOMA-3 study (NCT01942135) of palbociclib in combination
with fulvestrant in women (any menopausal status) with
HR+, HER2-negative advanced breast cancer after failure on
endocrine therapy, palbociclib significantly increased PFS com-
pared with placebo (median PFS 9.2 vs 3.8 months; HR = 0.42; 95%
CI 0.32–0.56; p < 0.001) [65]. Palbociclib is additionally under
investigation in the adjuvant and neoadjuvant settings. For exam-
ple, a phase III trial of adjuvant palbociclib with standard endocrine
therapy is ongoing in patients with HR+, HER2-negative breast can-
cer with residual disease after neoadjuvant chemotherapy and sur-
gery (PENELOPE-B; NCT01864746). A phase II neoadjuvant study of
palbociclib in combination with letrozole is also ongoing in
ER+, HER2-negative breast cancer (PALLET; NCT02296801) [64].
Combination of ribociclib plus letrozole has been investigated
in a phase Ib study for first-line treatment of postmenopausal
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(NCT01872260) [64]; preliminary data suggest an acceptable
safety profile and signs of clinical activity [66]. A phase III trial of
ribociclib plus letrozole in this setting has now completed accrual
of postmenopausal patients with advanced HR+, HER2-negative
breast cancer (NCT01958021; MONALEESA-2) [64]. A companion
study for premenopausal patients with HR+, HER2-negative
advanced breast cancer (NCT02278120; MONALEESA-7) is investi-
gating ribociclib plus the gonadotropin-releasing hormone agonist,
goserelin, in combination with a non-steroidal aromatase inhibitor
(NSAI; letrozole or anastrozole) or tamoxifen and is currently
accruing patients [64]. The combination of ribociclib with fulves-
trant is being investigated in the first- and second-line setting in
the phase III MONALEESA-3 trial (NCT02422615), which is enrol-
ling postmenopausal patients with advanced HR+, HER2-negative
breast cancer [64].
The success of single-agent abemaciclib in HR+ metastatic
breast cancer prompted expansion of the phase I study to evaluate
abemaciclib (200 mg twice daily) in combination with the
anti-estrogen fulvestrant (500 mg once monthly) in this patient
population. In an interim analysis, 18 patients with a median of
4 prior systemic therapies had been treated; combination
treatment had an acceptable safety profile and achieved a disease
control rate of 72% [67]. Abemaciclib is also being investigated in
combination with endocrine or HER2-targeted therapies in a phase
Ib study in metastatic breast cancer [68]. Phase III studies that are
underway in postmenopausal breast cancer include the MONARCH
2 study (NCT02107703) of abemaciclib plus fulvestrant in
advanced HR+, HER2-negative breast cancer and the MONARCH 3
study (NCT02246621) of abemaciclib in combination with an
NSAI (letrozole or anastrozole) in recurrent or metastatic
HR+, HER2-negative breast cancer [64].
PI3K/AKT/mTOR pathway inhibitors
The PI3K/AKT/mTOR pathway is a key upstream regulator of
cyclin D-CDK4/6 activity. In preclinical studies, palbociclib had an
additive effect on cell death in pancreatic ductal adenocarcinoma
(PDA) cell lines when combined with MEK or PI3K/mTOR inhibitors
[69]. Additionally, combination of palbociclib with the mTOR
complex 1 inhibitor everolimus synergistically inhibited the
growth of NSCLC cell lines [70]. Single-agent ribociclib inhibited
tumor growth in ER+ xenograft models, and this inhibition was
further enhanced by the addition of letrozole or fulvestrant. The
greatest tumor inhibition was observed with the triplet combina-
tion of ribociclib plus a PI3K inhibitor (buparlisib [BKM120] or
alpelisib [BYL719]) and letrozole or fulvestrant [61].
Based on this preclinical work, there is significant interest in
using CDK4/6 inhibitors in triplet combinations with endocrine
therapy and an inhibitor of the PI3K/AKT/mTOR pathway.
A randomized phase Ib study in ER+, HER2-negative advanced
breast cancer (NCT01872260) is investigating the efficacy of first-
line triplet therapy with ribociclib, letrozole, and alpelisib
[64,71]. A phase Ib trial of combination ribociclib, everolimus,
and exemestane in patients with ER+, HER2-negative metastatic
breast cancer (NCT01857193) is also ongoing [64,72]. Similarly, a
study of ribociclib and fulvestrant with or without buparlisib or
alpelisib in patients with pretreated ER+, HER2-negative locally
advanced or metastatic cancer is ongoing (NCT02088684) [64].
In a preclinical study, ribociclib also demonstrated synergistic
activity with the PI3K inhibitors pictilisib (GDC-0941) or alpelisib
in PI3K inhibitor-resistant, PIK3CA-mutant breast cancer cell lines,
and produced tumor regression in PIK3CA-mutant breast cancer
mouse models [73]. The phase II FERGI study, reported at the
San Antonio Breast Cancer Symposium in 2014, showed a modest,
non-statistically significant benefit (6.6 vs 5.1 months, HR = 0.74;p = 0.0959) associated with the addition of pictilisib to fulvestrant
in aromatase inhibitor-resistant, HR+ metastatic breast cancer [74].
Interestingly, although there was no increased benefit in
PIK3CA-mutated tumors, there was an improved response in
patients with PgR+ tumors (median PFS, 7.4 vs 3.7 months;
p = 0.002) [74]. Further investigations will be necessary to evaluate
the potential role of CDK4/6 and PI3 K pathway inhibitor combina-
tions for treating HR+ breast cancer, and for determining biomark-
ers that are predictive of response.
RAS/RAF/MEK/ERK pathway inhibitors
Combination of CDK4/6 inhibitors with RAS/RAF/MEK/ERK
pathway inhibitors is a promising therapeutic approach, particu-
larly in patients with melanoma. The FDA has approved BRAF
and MEK inhibitors both individually and in combination for
patients with BRAF V600-mutant melanomas [75]. Despite high
initial response rates, acquired resistance often develops faster
than desired, limiting the durability of response with these
targeted therapies. The addition of a CDK4/6 inhibitor has the
potential to overcome some of these resistance mechanisms [76,77].
Melanoma cell lines and tumor models that are resistant to the
BRAF inhibitor vemurafenib have reactivated MAPK signaling and
upregulated cyclin D1, and are sensitive to abemaciclib
treatment [76]. A phase Ib/II study combining ribociclib with the
MEK inhibitor binimetinib (MEK162) is ongoing in patients with
NRAS-mutant melanoma (n = 14; NCT01781572); one patient
achieved a confirmed PR, and unconfirmed PRs were reported in
a further five patients [77]. Although no pharmacokinetic
interaction was observed, finding the right dose and schedule to
maximally inhibit both pathways while minimizing toxicity
remains important; treatment-related toxicities were common
and included creatinine phosphokinase elevation, rash, edema,
anemia, nausea, diarrhea, and fatigue. Triplet combinations of
ribociclib with BRAF and MEK inhibitors are also currently being
explored [64].
Chemotherapy
Preclinical studies show conflicting results regarding the benefit
of combining CDK4/6 inhibitors with standard cytotoxic
chemotherapy. Abemaciclib enhanced the antitumor effect of gem-
citabine in a lung cancer xenograft model [37] and CDK4/6 inhibi-
tion sensitized neuroblastoma cells to doxorubicin-induced
apoptosis [78]; in contrast, palbociclib reduced the cytotoxicity
of antimitotics and platinum agents in preclinical models
[32,69,79]. Interestingly, six PRs were recorded in a phase I trial
of patients with pretreated, Rb+ metastatic breast cancer who
received a combination of palbociclib and paclitaxel (n = 15;
NCT01320592) [80]. In this study, uncomplicated grade 3/4 neu-
tropenia frequently led to dose reduction or dose interruption,
and an expansion study is underway to investigate the effect of a
3-day (rather than 5-day) dosing schedule [80]. Thus, even if
CDK4/6 inhibitors are found to improve the antitumor effects of
chemotherapy, the ability to circumvent the overlapping toxicity
of bone marrow suppression will remain a challenge in the clinic.
Radiotherapy
Emerging data suggest that inhibition of the
cyclin D-CDK4/6-INK4-Rb pathway may sensitize cell lines to
radiotherapy. A subpopulation of tumor cells, referred to as cancer
stem cells, is typically resistant to radiotherapy [81]. These cells
proliferate slowly, remain in a quiescent state for extended periods
of time, and have the ability to reconstitute tumors [81]. Evidence
points to a role for the cyclin D-CDK4/6-INK4-Rb pathway in
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cancer stem cells. Repression of CDK4 by the NFATc1 transcription
factor appears to be involved in maintenance of quiescence in hair
follicle stem cells [82]. In hematopoietic stem cells, CDK6 report-
edly acts as a regulator of quiescence exit, with the absence of
CDK6 protein resulting in a notable delay in quiescence exit [83].
In a study of a BCR-ABLp210+-induced leukemia cell line,
CDK6-deficient stem cells tended to remain in the quiescent state
compared with CDK6-proficient stem cells [84]. In addition, mice
injected with CDK6-proficient BCR-ABLp210+ bone marrow devel-
oped leukemia within 3 months, whereas mice injected with
CDK6-deficient BCR-ABLp210+ bone marrow generally failed to
develop disease, further supporting a role for CDK6 in cancer stem
cell activity [84]. In triple-negative breast cancer cell lines,
Rb-deficient cancer stem cells exhibited increased response to
radiotherapy compared with Rb-proficient cancer stem cells [85].
Radiotherapy-resistant cancer stem cells isolated from liver cancer
and glioblastoma cell lines demonstrated upregulation of AKT and
cyclin D-CDK4 signaling; inhibition of AKT, cyclin D, or CDK4
resulted in re-sensitization to radiotherapy in these cells [86]. In
another study, radiotherapy-resistant cell lines knocked down for
CDK4 demonstrated radiosensitivity, while cells knocked down
for CDK2 were not re-sensitized [87]. This study also suggested
that silencing CDK4/6 increases radiation-induced cell death but
does not significantly alter cell cycle progression or interfere with
DNA repair following radiation exposure [87]. The mechanism of
CDK4/6 inhibitor radiosensitization may be related to the induc-
tion of cancer stem cell differentiation, which increases the vulner-
ability of cells to radiation-induced cell death [88]. The possible
clinical benefits of CDK4/6 blockade on radiation sensitization
need to be further explored.Conclusions
Dysregulated activation of the cyclin D-CDK4/6-INK4-Rb path-
way is frequently observed in a range of tumor types, and
CDK4/6 has emerged as a promising therapeutic target. As a
monotherapy, further efforts to refine a clear patient selection
strategy and understand the mechanisms of acquired resistance
will facilitate further development of CDK4/6 inhibitors in other
patients beyond HR+ breast cancer. Factors such as differing dosing
schedules (once daily with palbociclib and ribociclib versus twice
daily with abemaciclib) and side effect profiles (largely hematolog-
ical adverse events with palbociclib and ribociclib versus gastroin-
testinal effects with abemaciclib) may further influence clinical
decisions regarding how CDK4/6 inhibitors are used in individual-
ized patient care. Addition of CDK4/6 inhibitors to a variety of
established treatments has the potential to improve responses to
other therapies and may help overcome treatment resistance; in
particular, the combination of CDK4/6 inhibitors with endocrine
therapy is already FDA approved, and is expected to further trans-
form the treatment of HR+ breast cancer.Role of the funding source
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